Search clinical trials for: C1-esterase inhibitor - subcutaneous high dose

Total 418 results

CSL Behring
Parexel

Completed

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Hereditary Angioedema Types I and II

United States, Germany
AO GENERIUM

Withdrawn

Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

Hereditary Angioedema

Russian Federation
CSL Behring

Completed

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Shire

Completed

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Hereditary Angioedema

United States
CSL Behring

Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Antibody-mediated Rejection

United States, Spain, France, Netherlands, United Kingdom, Belgium, Germany
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Treatment-Resistant Depression

Spain, Japan, Poland, United States
CSL Behring

Completed

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Germany, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Shire

Completed

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks (CHANGE 3)

Hereditary Angioedema

United States
Shire

Completed

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Graft Rejection

United States, Germany
IMMUNOe Research Centers

Completed

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

CVI - Common Variable Immunodeficiency

United States
CSL Behring
Chiltern International Inc.

Completed

Patient Registry Study of Berinert® in Normal Clinical Practice

Includes: Hereditary Angioedema

United States, Denmark, Germany, Switzerland
Shire

Completed

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

United States
Shire

Completed

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

Hereditary Angioedema (HAE)

United States
Stanley Jordan, MD
CSL Behring

Completed

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Kidney Transplantation

United States
CSL Behring

Completed

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Hereditary Angioedema

United States, Canada
Radboud University Medical Center

Completed

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia (VECTOR)

Inflammation | Endotoxemia | Multi Organ Dysfunction Syndrome

Netherlands
Haaglanden Medical Centre
Takeda; Leiden University Medical Center

Not yet recruiting

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (CIAO@SAH)

Subarachnoid Hemorrhage, Aneurysmal
Cedars-Sinai Medical Center
OneLegacy Foundation

Active, not recruiting

Berinert (C1INH) vs Placebo for DGF/IRI

Chronic Kidney Diseases | End Stage Renal Disease

United States
Shire

Completed

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

United States
Shire

Completed

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks (CHANGE 2)

Hereditary Angioedema

United States
Shire

Completed

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Hereditary Angioedema

United States
Michael Levy
ViroPharma

Completed

C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation

Neuromyelitis Optica

United States
Johann Wolfgang Goethe University Hospital
CSL Behring; University of Milan; PharmaPart; Clinical trial center Rhine-Main; ZKI... and other collaborators

Completed

Berinert P Study of Subcutaneous Versus Intravenous Administration (PASSION)

Hereditary Angioedema

Germany
Shire

Completed

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Hereditary Angioedema (HAE)

Spain, Israel, United States, Hungary, Germany, Canada, Romania
Cedars-Sinai Medical Center

Completed

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI (C1INHDGF)

End Stage Renal Disease | Ischemic Reperfusion Injury | Kidney Failure | Delayed Graft Function

United States
UMC Utrecht
Prothya Biosolutions

Terminated

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture (CAESAR)

Sepsis | Inflammation | Trauma | Multiple Organ Dysfunction Syndrome

Netherlands
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Shire

Completed

Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks

Hereditary Angioedema (HAE)

United States, Germany, Spain, Sweden
University Hospital, Basel, Switzerland
Pharming Technologies B.V.; Clinical Trial Unit, University Hospital Basel,...

Completed

Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT)

Acute Kidney Injury

Switzerland
CSL Behring

Completed

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Bulgaria, United States, Poland, Spain, Hungary, United Kingdom, Russian Federation, Macedonia, The Former Yugoslav Republic of, Argentina, Australia, Canada, Czech Republic, Israel, Romania, Sweden
Radboud University Medical Center
UMC Utrecht; Prothya Biosolutions

Completed

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II (VECTORII)

Sepsis | Inflammation | Endotoxemia | Innate Immune Response

Netherlands
Penn State University

Withdrawn

C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation

Hereditary Angioedema
Queen Mary University of London

Completed

The Effect of Food Supplements on Food Intake and Gut Hormone Levels

Obesity | Endocrine; Obesity | Appetite; Perverted

United Kingdom
National Cancer Institute, Egypt

Recruiting

Low Dose Versus High Dose Methylene Blue in Septic Patients

Septic Shock

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Denmark, Estonia, Hungary, Italy, Lebanon, Malaysia, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Spain, Sweden, Taiwan
Shire

Terminated

A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

Acute Antibody-Mediated Rejection (AMR)

United States, Spain, France, Netherlands, Germany, Canada
University of Bonn
University of Hohenheim

Completed

Plasma Appearance of Xanthohumol in Healthy Adults

Plasmakinetics of Xanthohumol

Germany
Gilead Sciences

Not yet recruiting

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

HIV-1-infection
Shire

Completed

Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
Boehringer Ingelheim

Completed

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

HIV Infections
Boehringer Ingelheim

Completed

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Japan
Wake Forest University Health Sciences

Completed

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

Hyperglycemia | Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

BIBR 277 Capsule in Patients With Essential Hypertension

Hypertension
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours

Neoplasms

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Italy, Japan, Korea, Republic of, Malaysia and more
Hunan Province Tumor Hospital

Completed

ICI-combined Strategies Presented With Promising Efficacy in NSCLC Patients

Non Small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim

Terminated

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

HIV Infections
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States

3

Subscribe